These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38491776)

  • 1. Establishment and methodological evaluation of a chemiluminescence assay for detection of anti-envelope protein (E1, E2) antibodies in the serum of hepatitis C virus-infected patients.
    Wang N; Liu Q; Che F; Sun Q; Wang Y; Yang C; Dai Y; Cheng J
    J Clin Lab Anal; 2024 Feb; 38(4):e25011. PubMed ID: 38491776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Detection of serum anti-NS2 antibody and recombinant hepatitis C virus nonstructural protein 2 (NS2): its development and evaluation].
    Yu Y; Cheng J; Dai Y; Mei C
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Apr; 38(4):361-367. PubMed ID: 35583066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of hepatitis C virus envelope proteins expressed in E. coli and insect cells for use as tools for antibody screening.
    Hüssy P; Faust H; Wagner JC; Schmid G; Mous J; Jacobsen H
    J Hepatol; 1997 Jun; 26(6):1179-86. PubMed ID: 9210602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: effects of hepatitis B virus co-infection and interferon treatment.
    Zampino R; Marrone A; Durante Mangoni E; Santarpia L; Sica A; Tripodi MF; Utili R; Ruggiero G; Adinolfi LE
    J Med Virol; 2004 May; 73(1):33-7. PubMed ID: 15042645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees.
    Bassett SE; Thomas DL; Brasky KM; Lanford RE
    J Virol; 1999 Feb; 73(2):1118-26. PubMed ID: 9882313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of human clones producing neutralizing human monoclonal antibodies to the envelope E1/E2 protein of hepatitis C virus by EBV immortalization of immune CD22⁺ B cells.
    Tabll A; El Abd Y; El Din NG; El Shenawy R; Abdelhafez TH; El Awady M; El-Mohamady H; Viazov S
    Hum Antibodies; 2013; 22(3-4):55-65. PubMed ID: 24961863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment and Evaluation of Recombinant Expression of HCV Transmembrane Protein (p7) and Detection of Anti-p7 Antibody in Serum of HCV-Infected Patients by Chemiluminescence.
    Zhou H; Wu J; Yu Y; Dai Y; Jin X; Sun Q; Che F; Zhang Y; Cheng J
    Lab Med; 2023 May; 54(3):299-307. PubMed ID: 36300840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody responses to hepatitis C envelope proteins in patients with acute or chronic hepatitis C.
    Fournillier-Jacob A; Lunel F; Cahour A; Cresta P; Frangeul L; Perrin M; Girard M; Wychowski C
    J Med Virol; 1996 Oct; 50(2):159-67. PubMed ID: 8915882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the role of neutralizing antibodies against envelope genes in resolving HCV pseudo-particles infection.
    Rafique S; Idrees M; Ali A; Iqbal M
    Mol Biol Rep; 2014 Jun; 41(6):3945-50. PubMed ID: 24566682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perinatal transmission of hepatitis C antigens: envelope 1, envelope 2 and non-structural 4.
    Attallah AM; Abdallah SO; El-Far M; Omran MM; Tabll AA; Ghaly MF; Ezzat SM; Elhamshary MO; El-Gohary ZM; Mohamedin AH; El-Morsi AA; Askora AA; Abdelrazek MA; El-Kafrawy HM; Keneber MH; Khalil MR; Aggag MM; Elbendary MS; El-Deeb MM; Abuzaid MS; Mansour AT; Attallah AA
    Infect Dis (Lond); 2015 Aug; 47(8):568-74. PubMed ID: 25922972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis of Hepatitis C Virus Infection Using a Novel Mouse Monoclonal Antibody to Detect Serum HCV E1/E2 Antigens.
    Touni I; Tabll AA; Sobieh SS; Hewedy MA; Abd YS; Viazov S
    Clin Lab; 2017 Apr; 63(4):669-678. PubMed ID: 28397481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers.
    Depraetere S; Van Kerschaever E; Van Vlierberghe H; Elewaut A; Brouwer JT; Niesters HG; Schalm SW; Maertens G; Leroux-Roels G
    J Med Virol; 2000 Feb; 60(2):126-32. PubMed ID: 10596010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies to hepatitis C virus envelope proteins correlate with hepatitis C viraemia after liver transplantation.
    Gane EJ; Maertens G; Ducatteeuw A; Qian KP; Lau JY; Jones H; Davies E; Naoumov NV; Williams R
    Transplantation; 1999 Jan; 67(1):78-84. PubMed ID: 9921800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.
    Rosa D; Campagnoli S; Moretto C; Guenzi E; Cousens L; Chin M; Dong C; Weiner AJ; Lau JY; Choo QL; Chien D; Pileri P; Houghton M; Abrignani S
    Proc Natl Acad Sci U S A; 1996 Mar; 93(5):1759-63. PubMed ID: 8700831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping of a conformational epitope shared between E1 and E2 on the serum-derived human hepatitis C virus envelope.
    Petit MA; Jolivet-Reynaud C; Peronnet E; Michal Y; Trépo C
    J Biol Chem; 2003 Nov; 278(45):44385-92. PubMed ID: 12882983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein.
    Helle F; Goffard A; Morel V; Duverlie G; McKeating J; Keck ZY; Foung S; Penin F; Dubuisson J; Voisset C
    J Virol; 2007 Aug; 81(15):8101-11. PubMed ID: 17522218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
    Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Hepatitis C Virus Core and E2 antigenic recombinant proteins and their use for development of diagnostic assays.
    Ali A; Nisar M; Idrees M; Rafique S; Iqbal M
    Int J Infect Dis; 2015 May; 34():84-9. PubMed ID: 25796431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus E1 recruits high-density lipoprotein to support infectivity and evade antibody recognition.
    Casiano Matos J; Harichandran K; Tang J; Sviridov DO; Sidoti Migliore G; Suzuki M; Olano LR; Hobbs A; Kumar A; Paskel MU; Bonsignori M; Dearborn AD; Remaley AT; Marcotrigiano J
    J Virol; 2024 Jan; 98(1):e0084923. PubMed ID: 38174935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of antibody to hepatitis C virus E2 recombinant antigen among samples indeterminate for anti-HCV after wide serological testing and correlation with viremia. The Spanish Study Group for Blood Donors at Risk of Transmission of HCV.
    León P; López JA; Elola C; Domingo CJ; Echevarria JM
    Vox Sang; 1996; 70(4):213-6. PubMed ID: 9123926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.